Cellectis Reports Q2 2025 Financial Results and Business Update, Plans R&D Day for Investors, and Appoints New Board Member.

Cellectis reports Q2 2025 financial results and updates on its activities, including plans to hold an R&D Day in New York on October 16, 2025, to present phase 1 data and development strategy for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (LAL-B r/r). The company also announced the nomination of André Muller as an administrator to its board of directors and reported a cash, cash equivalents and term deposits balance of $230 million as of June 30, 2025.